期刊
CURRENT ALZHEIMER RESEARCH
卷 11, 期 2, 页码 165-174出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1567205010666131212114156
关键词
Alzheimer's disease neuroimaging initiative; Alzheimer's disease; apolipoprotein-E; leptin replacement; leptin; mild cognitive impairment
资金
- Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
- National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
- Canadian Institutes of Health Research
- NIH [P30 AG010129, K01 AG030514]
- National Institute on Aging [SBIR-5R44AG029670]
Analysis of data derived from the Alzheimer's Disease Neuroimaging Initiative (ADNI) program showed plasma leptin levels in individuals with Mild Cognitive Impairment (MCI) or Alzheimer's disease (AD) to be lower than those of subjects with normal cognition (NC). Approximately 70% of both men and women with MCI have plasma leptin levels lower than the median values of NC. Additionally, half of these subjects carry at least one apolipoprotein-E4 (APOE-epsilon 4) allele. A subgroup of participants also had cerebrospinal fluid (CSF) leptin measured. Plasma leptin typically reflected the levels of leptin in CSF in all groups (Control/MCI/AD) in both genders. The data suggest that plasma leptin deficiency provides an indication of potential CNS leptin deficiency, further supporting the exploration of plasma leptin as a diagnostic marker for MCI or AD. The important question is whether leptin deficiency plays a role in the causation of AD and/or its progression. If this is the case, individuals with early AD or MCI with low plasma leptin may benefit from leptin replacement therapy. Thus, these data indicate that trials of leptin in low leptin MCI/early-stage AD patients should be conducted to test the hypothesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据